Global Health Data Exchange - Discover the World's Health Data

The safety of double- and triple-drug community mass drug administration for lymphatic filariasis: A multicenter, open-label, cluster-randomized study

Nav

General Info
Geography 
Fiji (FJI)
India (IND)
Indonesia (IDN)
Nord
Time period covered 
01/2016 - 12/2017
Citation
Authors 
Weil GJ, Bogus J, Christian M, Dubray C, Djuardi Y, Fischer PU, Goss CW, Hardy M, Jambulingam P, King CL, Kuttiat VS, Krishnamoorthy K, Laman M, Lemoine JF, O'Brian KK, Robinson LJ, Samuela J, Schechtman KB, Sircar A, Srividya A, Steer AC, Supali T, Subramanian S, DOLF IDA Safety Study Group
Journal 
PLoS Med
Volume 
16
Issue 
6
Pages 
e1002839
Publication year 
2019
Suggested citation 
Weil GJ, Bogus J, Christian M, Dubray C, Djuardi Y, Fischer PU, Goss CW, Hardy M, Jambulingam P, King CL, Kuttiat VS, Krishnamoorthy K, Laman M, Lemoine JF, O'Brian KK, Robinson LJ, Samuela J, Schechtman KB, Sircar A, Srividya A, Steer AC, Supali T, Subramanian S, DOLF IDA Safety Study Group. The safety of double- and triple-drug community mass drug administration for lymphatic filariasis: A multicenter, open-label, cluster-randomized study. PLoS Med. 2019; 16(6): e1002839.
DOI 
10.1371/journal.pmed.1002839
PMID 
31233507